These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 16371515)

  • 21. Relationship between hospital volume and early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator.
    Wada T; Yasunaga H; Inokuchi R; Horiguchi H; Fushimi K; Matsubara T; Nakajima S; Yahagi N
    Int J Stroke; 2015 Jan; 10(1):73-8. PubMed ID: 25043743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effect of Age and Sex on Clinical Outcome after Intravenous Recombinant Tissue Plasminogen Activator Treatment in Patients with Acute Ischemic Stroke.
    Buijs JE; Uyttenboogaart M; Brouns R; de Keyser J; Kamphuisen PW; Luijckx GJ
    J Stroke Cerebrovasc Dis; 2016 Feb; 25(2):312-6. PubMed ID: 26527412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early ischemic change on CT versus diffusion-weighted imaging for patients with stroke receiving intravenous recombinant tissue-type plasminogen activator therapy: stroke acute management with urgent risk-factor assessment and improvement (SAMURAI) rt-PA registry.
    Nezu T; Koga M; Nakagawara J; Shiokawa Y; Yamagami H; Furui E; Kimura K; Hasegawa Y; Okada Y; Okuda S; Kario K; Naganuma M; Maeda K; Minematsu K; Toyoda K
    Stroke; 2011 Aug; 42(8):2196-200. PubMed ID: 21719764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prior Antithrombotic Use Is Associated With Favorable Mortality and Functional Outcomes in Acute Ischemic Stroke.
    Myint PK; Hellkamp AS; Fonarow GC; Reeves MJ; Schwamm LH; Schulte PJ; Xian Y; Suter RE; Bhatt DL; Saver JL; Peterson ED; Smith EE
    Stroke; 2016 Aug; 47(8):2066-74. PubMed ID: 27435402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes.
    Su TH; Chan YL; Lee JD; Lee M; Lin LC; Wen YW; Lee TH
    J Stroke Cerebrovasc Dis; 2016 Oct; 25(10):2439-47. PubMed ID: 27388708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mild stroke and advanced age are the major reasons for exclusion from thrombolysis in stroke patients admitted within 4.5 hours.
    Liu Y; Zhao H; Zhou J; Wang Q; Chen Z; Luo N
    J Stroke Cerebrovasc Dis; 2014 Jul; 23(6):1571-6. PubMed ID: 24582787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-Versus Standard-Dose Alteplase for Ischemic Strokes Within 4.5 Hours: A Comparative Effectiveness and Safety Study.
    Kim BJ; Han MK; Park TH; Park SS; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Lee J; Lee SJ; Ko Y; Park JM; Kang K; Cho YJ; Hong KS; Kim JT; Choi JC; Kim DE; Shin DI; Kim WJ; Lee J; Lee JS; Yoon BW; Gorelick PB; Bae HJ
    Stroke; 2015 Sep; 46(9):2541-8. PubMed ID: 26243232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is thrombolysis safe in the elderly?: analysis of a national database.
    Alshekhlee A; Mohammadi A; Mehta S; Edgell RC; Vora N; Feen E; Kale S; Shakir ZA; Cruz-Flores S
    Stroke; 2010 Oct; 41(10):2259-64. PubMed ID: 20829516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness of standard care with IV thrombolysis versus without IV thrombolysis for mild ischemic stroke.
    Choi JC; Jang MU; Kang K; Park JM; Ko Y; Lee SJ; Cha JK; Kim DH; Park SS; Park TH; Lee KB; Lee J; Kim JT; Cho KH; Yu KH; Oh MS; Lee BC; Cho YJ; Kim DE; Lee JS; Lee J; Gorelick PB; Bae HJ
    J Am Heart Assoc; 2015 Jan; 4(1):e001306. PubMed ID: 25628404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statin use and functional outcome after tissue plasminogen activator treatment in acute ischaemic stroke.
    Miedema I; Uyttenboogaart M; Koopman K; De Keyser J; Luijckx GJ
    Cerebrovasc Dis; 2010 Feb; 29(3):263-7. PubMed ID: 20090317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of Early Arterial Recanalization and Tissue Fate in the Selection of Patients With the Greatest Potential to Benefit From Intravenous Tissue-Type Plasminogen Activator.
    Leiva-Salinas C; Patrie JT; Xin W; Michel P; Jovin T; Wintermark M
    Stroke; 2016 Feb; 47(2):397-403. PubMed ID: 26696647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of the Cincinnati Prehospital Stroke Scale for identifying thrombolytic candidates in acute ischemic stroke.
    You JS; Chung SP; Chung HS; Lee HS; Park JW; Kim HJ; Lee SH; Park I; Lee HS
    Am J Emerg Med; 2013 Dec; 31(12):1699-702. PubMed ID: 24055479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombolytic therapy for stroke in patients with preexisting cognitive impairment.
    Murao K; Leys D; Jacquin A; Kitazono T; Bordet R; Béjot Y; Kimura K; Godefroy O; Wakisaka Y; Moulin S; Ago T; Sibon I; Bombois S; Mas JL; Hénon H; Pasquier F; Giroud M; Cordonnier C; Okada Y;
    Neurology; 2014 Jun; 82(23):2048-54. PubMed ID: 24827495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous recombinant tissue plasminogen activator for acute stroke in Poland: an analysis based on the Safe Implementation of Thrombolysis in Stroke (SITS) Registry.
    Kobayashi A; Czlonkowska A; Ahmed N; Romanowicz S; Glonek M; Nyka WM; Opala G; Wahlgren N;
    Acta Neurol Scand; 2010 Oct; 122(4):229-36. PubMed ID: 19919643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcome as function of blood pressure in acute ischemic stroke and effects of thrombolysis.
    Yong M; Diener HC; Kaste M; Mau J
    Cerebrovasc Dis; 2007; 24(4):349-54. PubMed ID: 17690547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator.
    Menon BK; Saver JL; Prabhakaran S; Reeves M; Liang L; Olson DM; Peterson ED; Hernandez AF; Fonarow GC; Schwamm LH; Smith EE
    Stroke; 2012 Sep; 43(9):2293-9. PubMed ID: 22811458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombolytic therapy with intravenous recombinant tissue plasminogen activator in Japanese older patients with acute ischemic stroke: Fukuoka Stroke Registry.
    Matsuo R; Kamouchi M; Ago T; Hata J; Shono Y; Kuroda J; Wakisaka Y; Sugimori H; Kitazono T;
    Geriatr Gerontol Int; 2014 Oct; 14(4):954-9. PubMed ID: 24320947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
    National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
    Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid profiles and outcome in patients treated by intravenous thrombolysis for cerebral ischemia.
    Nardi K; Engelter S; Strbian D; Sarikaya H; Arnold M; Casoni F; Ford GA; Cordonnier C; Lyrer P; Bordet R; Soinne L; Gensicke H; Duriez P; Baumgartner RW; Tatlisumak T; Leys D;
    Neurology; 2012 Sep; 79(11):1101-8. PubMed ID: 22843281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.